NextCure, Inc. Profile Avatar - Palmy Investing

NextCure, Inc.

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is i…

Biotechnology
US, Beltsville [HQ]

News

Theses · Events · Sentiments
End of NXTC's Analysis
CIK: 1661059 CUSIP: 65343E108 ISIN: US65343E1082 LEI: - UEI: -
Secondary Listings
NXTC has no secondary listings inside our databases.